VXRT - Altimmune: AdCOVID's Potential To Prevent Transmission May Be Key To Ending The Pandemic

• Biotechvalley Insights is upgrading ALT's rating to "Very Bullish" from a "Bullish" rating with a 12 month TP of US$52.
• Altimmune's (ALT) valuation is at a discount after the recent sell-off, and the fundamental picture has improved with more clarity around manufacturing.
• ALT has added new high-profile biotech investors on board, and institutional investors hold 75% of the float. This means the stock could potentially run 100-200% higher with a catalyst.
• AdCOVID has all the characteristics that WHO is looking for: sterilizing immunity (prevention of infection and transmission), safety, a single-dose administration, intranasal route of administration, and room temperature storage.
• The OWS vaccines do not prevent "transmission" and may not abate this pandemic. As such, COVID-19 may linger until the approval of an effective vaccine that can induce sterilizing immunity.

For further details see: